Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

High Stakes 2013

Click to download the PDF to view the full issue With the Zyprexa era over, Lilly is betting big on its ability to innovate in the pipeline. This past year was the first of three of what Lilly executives are calling the “YZ” years – the years after the expiration of patent protection for the […]

Read More »

Delivering Sustainable Growth 2013

Click to download the PDF to view the full issue J&J emerged from a transitional 2012 continuing to generate annual sales increases and make significant advances on multiple fronts; the company is building out strategic platforms and establishing new ones. Johnson & Johnson constitutes the broadest base of health-care businesses on a global scale. Seventy […]

Read More »

Brace For More Impact 2013

Click to download the PDF to view the full issue The worst is not yet over for the pharma industry. Despite a general sense from many companies that the worst of the impact from their blockbusters going off patent is passing and better times are ahead, there are still complex challenges that many are still […]

Read More »

Changing Gears 2013

Click to download the PDF to view the full issue Although the company’s long-time best seller Plavix fell off patent in 2012, a number of Bristol-Myers Squibb’s newer compounds – both already on the market and in the pipeline – are showing signs of future potential. For Bristol-Myers Squibb, 2012 was a year of strategic […]

Read More »

Still Going 2013

Click to download the PDF to view the full issue With revenue of more than $20 billion, the largest generics portfolio globally, the world’s leading multiple sclerosis product, and a growing presence in oncology, Teva has earned a place at the big kids’ table in the pharma world. The Teva train just kept rolling down […]

Read More »

Cliff Driving 2013

Click to download the PDF to view the full issue Battered by the expiration of exclusivity of blockbuster products, Sanofi is driven to grow other areas of its business. The patent cliff continued to take its toll on Sanofi during 2012 and first-half 2013. But executives believe that the worst is probably over and they […]

Read More »

Steady As She Goes 2013

Click to download the PDF to view the full issue Roche once again enjoyed growth in 2012 despite market difficulties, and the company continues its winning strategy of developing drugs for unmet needs and companion diagnostics. Despite increasing cost pressures in many markets, 2012 was a positive year for Roche, in which the company posted […]

Read More »

Refocused On Success 2013

Click to download the PDF to view the full issue As Pfizer continues to be weighed down by Lipitor’s patent expiration, the company has sold off its animal health business and is moving to internally split its commercial operations into three business segments. At Pfizer, there is a new slogan and a new attitude. As […]

Read More »

Q&A with Lars Rebien Sorensen 2013

Click to download the PDF to view the full issue Med Ad News: What do you feel are the major strategic and marketplace challenges today for a company such as Novo Nordisk, and how is the company meeting those challenges? LS: One of the challenges is one we share with all of the pharmaceutical companies, […]

Read More »

A sweet spot to be in, 2013

Click to download the PDF to view the full issue For Novo Nordisk in 2012, laser-focused strategy paid off once again with double-digit growth, despite the continuing difficulties in the world economy. Med Ad News’ Company of the Year had sales growth of almost 18 percent in 2012, and for the first half of 2013, […]

Read More »

Strategic Priority Progress 2013

Click to download the PDF to view the full issue A new wave of innovation, productivity, and growth is helping Novartis move past significant patent expirations into the next phase of growth for the company. Novartis capitalized on strong momentum from innovation, growth and productivity throughout 2012 in an effort to offset patent expirations to […]

Read More »

Long Term Strategy 2013

Click to download the PDF to view the full issue Amgen is concentrating on the product pipeline, international expansion, and its entry into the biosimilar market to drive company growth during the years ahead. Amgen executives cited 2012 as an exceptional year for the company. Amgen generated 11 percent revenue growth, 2 percent adjusted earnings […]

Read More »

First Steps 2013

Click to download the PDF to view the full issue The newborn AbbVie came into being at the beginning of 2013, bringing with it the world’s best-selling prescription product and the rest of the legacy Abbott Labs biopharmaceuticals portfolio. The legacy Abbott Laboratories had two major goals in 2012, one usual and one unusual. While […]

Read More »

Fighting Back 2013

Click to download the PDF to view the full issue Although the market-exclusivity loss of Singulair has hurt the company’s top line of late, Merck has plenty of high-potential products on the market and in the pipeline with which to recover. As one of the world’s largest pharmaceutical companies, Merck has more than enough wherewithal […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation